The economic benefits of preventing end-stage renal disease in patients with type 2 diabetes mellitus

Nephrology Dialysis Transplantation

Volumn 24, Issue 10, 2009, Pages 2975-2983

  Postma, Maarten J ^a   De Zeeuw, Dick ^b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Chronic kidney disease; Diabetic nephropathy; Economics; Proteinuria

Indexed keywords

ALBUMIN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; GLICLAZIDE; INDAPAMIDE PLUS PERINDOPRIL; IRBESARTAN; LOSARTAN; PLACEBO; RAMIPRIL; ROSIGLITAZONE; TELMISARTAN; TRANDOLAPRIL; VERAPAMIL;

ALBUMIN BLOOD LEVEL; ALLELE; ANTIHYPERTENSIVE THERAPY; BELGIUM; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIABETES CONTROL; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG COST; DRUG MEGADOSE; FOLLOW UP; FRANCE; GENETIC POLYMORPHISM; GERMANY; GLOMERULUS FILTRATION; HEALTH CARE COST; HUMAN; HUNGARY; INDEL MUTATION; ITALY; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIFE EXPECTANCY; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEINURIA; QUALITY OF LIFE; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SPAIN; UNITED KINGDOM; UNITED STATES; VASCULAR DISEASE;

DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; ECONOMICS, PHARMACEUTICAL; HUMANS; KIDNEY FAILURE, CHRONIC;

EID: 70349512250     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp352     Document Type: Review

References (85)

1. Gansevoort RT, Van Der Heij B, Stegeman CA et al. Trends in the incidence of treated end-stage renal failure in The Netherlands: hope for the future? Kidney Int Suppl 2004: S7-S10
2. Stewart JH, McCredie MR, Williams SM. Divergent trends in the incidence of end-stage renal disease due to Type 1 and Type 2 diabetes in Europe, Canada and Australia during 1998-2002. Diabet Med 2006; 23: 1364-1369
3. Rutkowski B. Changing pattern of end-stage renal disease in central and eastern Europe. Nephrol Dial Transplant 2000; 15: 156-160
4. Stengel B, Billon S, Van Dijk PC et al. Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999. Nephrol Dial Transplant 2003; 18: 1824-1833
5. Grassmann A, Gioberge S, Moeller S et al. ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends. Nephrol Dial Transplant 2005; 20: 2587-2593
6. Coresh J, Selvin E, Stevens LA et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-2047 (Pubitemid 350074801)
7. Hallan SI, Coresh J, Astor BC et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol 2006; 17: 2275-2284
8. de Zeeuw D, Hillege HL, de Jong PE. The kidney, a cardiovascular risk marker, and a new target for therapy. Kidney Int Suppl 2005; S25-S29 (Pubitemid 43307845)
9. Gowdak LH, Arantes RL, de Paula FJ et al. Underuse of American College of Cardiology/American Heart Association Guidelines in hemodialysis patients. Ren Fail 2007; 29: 559-565
10. Keane WF, ZhangZ,Lyle PAet al.Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study. Clin J Am Soc Nephrol 2006; 1: 761-767
11. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007; 116: 85-97
12. Vora JP, Ibrahim HA, Bakris GL. Responding to the challenge of diabetic nephropathy: the historic evolution of detection, prevention and management. J Hum Hypertens 2000; 14: 667-685
13. Zoccali C, Mallamaci F, Tripepi G. Traditional and emerging cardiovascular risk factors in end-stage renal disease. Kidney Int Suppl 2003: S105-S110 (Pubitemid 36605875)
14. World Health Organization. Diabetes. Fact sheet N 312. 2008; http://www.who.int/mediacentre/factsheets/fs312/en/index.html. Accessed 8 June 2009
15. Agarwal R, Curley TM. The role of statins in chronic kidney disease. Am J Med Sci 2005; 330: 69-81
16. SukhijaR,BursacZ,Kakar Pet al.Effectofstatinsonthe development of renal dysfunction. Am J Cardiol 2008; 101: 975-979
17. Deferrari G, Ravera M, Berruti V et al. Optimizing therapy in the diabetic patient with renal disease: antihypertensive treatment. J Am Soc Nephrol 2004; 15(Suppl 1): S6-S11
18. Fox CS, Larson MG, Leip EP et al. Glycemic status and development of kidney disease: the Framingham Heart Study. Diabetes Care 2005; 28: 2436-2440
19. Levin A. Identification of patients and risk factors in chronic kidney disease-evaluating risk factors and therapeutic strategies. Nephrol Dial Transplant 2001; 16(Suppl 7): 57-60
20. Hansson L, Zanchetti A, Carruthers SG et al. HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762 (Pubitemid 28269185)
21. Consulting on the patient with type 2 diabetes: matching medication to disease mechanism. Manag Care 2007; 16: 2-11
22. Gaede P, Vedel P, Larsen N et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393 (Pubitemid 36159355)
23. Gaede P, Vedel P, Parving HH et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbu-minuria: the Steno type 2 randomised study. Lancet 1999; 353: 617-622
24. Durand-Zaleski I, Combe C, Lang P. International Study of Health Care Organization and Financing for end-stage renal disease in France. Int J Health Care Finance Econ 2007; 7: 171-183
25. Trivedi HS, Pang MM, Campbell A et al. Slowing the progression of chronic renal failure: economic benefits and patients' perspectives. Am J Kidney Dis 2002; 39: 721-729
26. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853
27. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). Br Med J 1998; 317: 703-713
28. Patel A, MacMahon S, Chalmers J et al.Effectsof a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829-840
29. Deferrari G, Ravera M, Deferrari L et al. Renal and cardiovascular protection in type 2 diabetes mellitus: angiotensin II receptor blockers. J Am Soc Nephrol 2002; 13(Suppl 3): S224-S229
30. Ryden L, Standl E, Bartnik M et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: 88-136
31. Schrier RW, Estacio RO, Mehler PS et al. Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial. Nat Clin Pract Nephrol 2007; 3: 428-438
32. Meredith PA, Ostergren J. From hypertension to heart failure-are there better primary prevention strategies? J Renin Angiotensin Aldosterone Syst 2006; 7: 64-73
33. Weir MR. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? Clin Ther 2007; 29: 1803-1824
34. Montalescot G, Collet JP. Preserving cardiac function in the hypertensive patient: why renal parameters hold the key. Eur Heart J 2005; 26: 2616-2622
35. Parving HH, de Zeeuw D, Cooper ME et al. ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy. J Am Soc Nephrol 2008; 19: 771-779
36. Costa-Scharplatz M, van Asselt AD, Bachmann LM et al. Cost-effectiveness of pharmacogenetic testing to predict treatment response to angiotensin- converting enzyme inhibitor. Pharmacogenet Genomics 2007; 17: 359-368
37. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus: Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab 2004; 30: 487-496
38. Bosch J, Yusuf S, Gerstein HC et al. Effect of ramipril onthe incidence of diabetes. N Engl J Med 2006; 355: 1551-1562
39. Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003 (Pubitemid 34286536)
40. Ruggenenti P, Fassi A, Ilieva AP et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941-1951
41. Parving HH, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878 (Pubitemid 34940826)
42. Makino H, Haneda M, Babazono T et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 2007; 30: 1577-1578
43. Schmieder RE, Schrader J, Zidek W et al. Low-grade albuminuria and cardiovascular risk: what is the evidence? Clin Res Cardiol 2007; 96: 247-257
44. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259
45. Gaede P, Lund-Andersen H, Parving HH et al. Effect of a multifacto-rial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-591
46. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-1187 (Pubitemid 46924065)
47. Lindholm LH, Ibsen H, Dahlof B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004-1010 (Pubitemid 34286537)
48. Ravid M, Brosh D, Levi Z et al. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1998; 128: 982-988
49. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869 (Pubitemid 34940825)
50. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effectofthe angiotensin-receptor antagonist irbesartan in patients with nephropa-thy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860
51. Kidney Disease Outcomes Quality Initiative. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43: S1-S290
52. Mann JF, Schmieder RE, McQueen M et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ON-TARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547-553
53. Maione A, Nicolucci A, Craig JC et al. Protocol of the Long-term Impact of RAS Inhibition on Cardiorenal Outcomes (LIRICO) randomized trial. J Nephrol 2007; 20: 646-655
54. ClinicalTrials.gov. VA NEPHRON-D Study (CSP#565) [NCT 00555217] 2009. http://clinicaltrials.gov/ct2/show/NCT00555217. Accessed 8 June 2009
55. Barnett AH, Bain SC, Bouter P et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropa-thy. N Engl J Med 2004; 351: 1952-1961
56. Hou FF, Xie D, Zhang X et al. Renoprotection of Optimal Antipro-teinuric Doses (ROAD) Study: a randomized controlled study of be-nazepril and losartan in chronic renal insufficiency. J Am Soc Nephrol 2007; 18: 1889-1898
57. Atthobari J, Asselbergs FW, Boersma C et al. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events:apharmacoeconomic analysis linkedto the prevention of renal and vascular end-stage disease (PREVEND) study and the prevention ofrenal and vascular end-stage disease intervention trial (PREVEND IT). Clin Ther 2006; 28: 432-444
58. Caro JJ, Ward AJ, O'Brien JA. Lifetime costs of complications resulting from type 2 diabetes in the US. Diabetes Care 2002; 25: 476-481
59. Palmer AJ, Annemans L, Roze S et al. An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT)in the Belgian and French settings. Nephrol Dial Transplant 2003; 18: 2059-2066
60. van Os N, Niessen LW, Bilo HJ et al. Diabetes nephropathy in the Netherlands: a cost effectiveness analysis of national clinical guidelines. Health Policy 2000; 51: 135-147
61. Lamping DL, Constantinovici N, Roderick P et al. Clinical outcomes, quality of life, and costs in the North Thames Dialysis Study of elderly people on dialysis: a prospective cohort study. Lancet 2000; 356: 1543-1550
62. Vora J, Carides G, Robinson P. Effects of losartan-based therapy on the incidence of end-stage renal disease and associated costs in type 2 diabetes mellitus: a retrospective cost-effectiveness analysis in the United Kingdom. Curr Ther Res 2005; 66: 475-485
63. Gerth WC, Remuzzi G, Viberti G et al. Losartan reduces the burden and cost of ESRD: Public health implications from the RENAAL study for the European Union. Kidney Int 2002; 62(Suppl 82): 68-72
64. Palmer AJ, Annemans L, Roze S et al. Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesar-tan treatment in patients with type 2 diabetes, hypertension, and renal disease. Diabetes Care 2004; 27: 1897-1903
65. Palmer AJ, Valentine WJ, Tucker DM et al. A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension. Curr Med Res Opin 2006; 22: 2095-2100
66. Boersma C, Atthobari J, Gansevoort RT et al. Pharmacoeconomics of angiotensin II antagonists in type 2 diabetic patients with nephropa-thy: implications for decision making. Pharmacoeconomics 2006; 24: 523-535
67. Palmer AJ, Annemans L, Roze S et al. An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting. J Hum Hypertens 2004; 18: 733-738
68. Palmer AJ, Tucker DM, Valentine WJ et al. Cost-effectiveness of irbesartan in diabetic nephropathy: a systematic review of published studies. Nephrol Dial Transplant 2005; 20: 1103-1109
69. Jonsson L, Carides GW, Burke TA et al. Cost-effective prevention of renal failure in type 2 diabetics using losartan. J Med Econ 2005; 8: 131-138
70. Souchet T, Durand Zaleski I, Hannedouche T et al. An economic evaluation of Losartan therapy in type 2 diabetic patients with nephropa-thy: an analysis of the RENAAL study adapted to France. Diabetes Metab 2003; 29: 29-35
71. Szucs TD, Sandoz MS, Keusch GW. The cost-effectiveness of losartan in type 2 diabetics with nephropathy in Switzerland-an analysis of the RENAAL study. Swiss Med Wkly 2004; 134: 440-447
72. Stafylas PC, Sarafidis PA, Grekas DM et al. A cost-effectiveness analysis of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in diabetic nephropathy. J Clin Hypertens (Greenwich) 2007; 9: 751-759
73. Palmer AJ. Health economics-what the nephrologist should know. Nephrol Dial Transplant 2005; 20: 1038-1041
74. Palmer AJ, Chen R, Valentine WJ et al. Cost-consequence analysis in a French setting of screening and optimal treatment of nephropathy in hypertensive patients with type 2 diabetes. Diabetes Metab 2006; 32: 69-76
75. Palmer AJ, Roze S, Valentine WJ et al. Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland. Swiss Med Wkly 2006; 136: 346-352
76. Palmer AJ, Annemans L, Roze S et al. Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria. Kidney Int Suppl 2005: S52-S54 (Pubitemid 40019217)
77. Palmer AJ, Valentine WJ, Ray JA et al. Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysis. Eur J Health Econ 2007; 8: 161-168
78. Palmer AJ, Valentine WJ, Chen R et al. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA. Nephrol Dial Transplant 2008; 23: 1216-1223
79. Gaede P, Valentine WJ, Palmer AJ et al. Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study. Diabetes Care 2008; 31: 1510-1515
80. Brantsma AH, Atthobari J, Bakker SJ et al. What predicts progression and regression of urinary albumin excretion in the nondiabetic population? J Am Soc Nephrol 2007; 18: 637-645
81. Golan L, Birkmeyer JD, Welch HG. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intern Med 1999; 131: 660-667
82. Postma MJ, Boersma C, Gansevoort RT. Pharmacoeconomics in nephrology: considerations on cost-effectiveness of screening for al-buminuria. Nephrol Dial Transplant 2008; 23: 1103-1106
83. Sandoz MS, Ess SM, Keusch GW et al. Prevalence and direct medical costs of end-stage renal disease in patients with type 2 diabetes mellitus in Switzerland for 2001. Swiss Med Wkly 2004; 134: 448-458
84. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053
85. VoorhamJ,Haaijer-Ruskamp FM, Stolk RPet al.Influenceofelevated cardiometabolic risk factor levels on treatment changes in type 2 diabetes. Diabetes Care 2008; 31: 501-503